Moderna MRNA · NASDAQ
$226.89 +4.07% (+$8.88)
Summary
17 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $1.72B against $1.29B.
- It beat profit estimates 8 times in the last 8 quarters.
What to watch
- Revenue fell by 53% a year over the last 3 years.
- The company made a loss over the last 12 months.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 19% a year over 5 years. Over the last 3 years it fell by 53% a year. For the next fiscal year analysts expect revenue to grow by 8.1%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $3.15B.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 8
- Hold 15
- Sell 6
Today's price within the analysts' price targets
The average target of $115.7 is 49% below today's price. 28% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- COVID 93%
- Stand-ready manufacturing revenue 4.1%
- Grant revenue 1.1%
- Collaboration revenue 0.7%
- Licensing and royalty revenue 0.6%
- Other 0.4%
By region
- UNITED STATES 65%
- Rest Of The World 33%
- Europe 2.9%
COVID brings in 93% of revenue.
Segments in detail